Interested in linking to "Pfizer Reinvents Lean in the Lab"?
You may use the Headline, Deck, Byline and URL of this article on your Web site. To link to this article, select and copy the HTML code below and paste it on your own Web site.
By Lorcan Mannion, Operations Practice Manager, BSM Ireland, and Ciarán Crosbie, Operational Excellence Specialist, Pfizer
Since the term “Lean” was first coined in 1990(to describe the manufacturing approach being used in Toyota factories in Japan), the space has become littered with lean programs in their various guises, such as Lean Manufacturing, Six Sigma, and Lean Sigma. These programs are usually high on education, but often lack sufficient emphasis on the necessary paradigm change to make a real, sustained impact on a company’s work practices.
Furthermore, while the literature assures us that Lean Manufacturing principles can be applied to any business process, many lean programs outside of Manufacturing still struggle to make these principles relevant. In the Life Sciences, this failure means that a significant opportunity for cost savings in the business—in particular, Quality Control and Quality Assurance processes—is overlooked.
At the core of this missed opportunity is a subtle misunderstanding of the real intent of Lean. By its original definition, Lean is about “the complete and thorough elimination of wasteful practices.” Unfortunately many companies read this intent as simply “elimination of waste.” This intuitively leads them down the trail of setting up projects which address only one of the three wasteful practices—the one called muda in the original Japanese texts.
There are various types of muda described in the Lean literature: Overproduction, Delays (Waiting), Transporting, Moving, Over-Processing (Rework), Inventory, Making Defective Parts. Chasing down muda is intuitively straightforward. Everyone on a project team can contribute to drawing a Value Stream Map. Indeed, this is a good tool to help everyone to see the Value-Add activities in their process and separate them from the Non-Value-Add (NVA) muda. It is also, then, relatively intuitive to go about addressing the wasteful NVA activities, so that wastes such as excessive movement (of product, samples, batch records, etc.), or causes of rework, invalid tests, and corrections can be reduced or eliminated.
ADVERTISEMENT

Furthermore, many companies have read about “product flow” and about the wonderful aspiration of “one-piece-flow.” Then, because it seems impossible, they quickly convince themselves that “we are different” and “that won’t work here (or in this part of the business) because . . . .” They don’t go the extra mile to try to understand more fully what it is about their business (or their part of the business) that is different, and make the necessary adjustments. PharmaManufacturing.com is the site for knowledge, news and analysis for manufacturing and other professionals working in the pharmaceutical, biopharmaceutical and biotech industries.